Association of the OCTN1/1672T variant with increased risk for colorectal cancer in young individuals and ulcerative colitis patients

Inflammatory Bowel Diseases

Volumn 18, Issue 3, 2012, Pages 439-448

  Martini, Maurizio ^a   Ferrara, Anna Maria ^a   Giachelia, Manuela ^a   Panieri, Emiliano ^a   Siminovitch, Katherine ^b   Galeotti, Tommaso ^a   Larocca, Luigi Maria ^a   Pani, Giovambattista ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

basic science; cancer in IBD; clinical; OCTN1; OCTN2

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GROUPS BY AGE; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; ULCERATIVE COLITIS;

CACO-2 CELLS; CELL TRANSFORMATION, NEOPLASTIC; CHI-SQUARE DISTRIBUTION; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN-8; MALE; MIDDLE AGED; NF-KAPPA B; ORGANIC CATION TRANSPORT PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, MESSENGER; STATISTICS, NONPARAMETRIC;

EID: 84857370196     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21814     Document Type: Article

References (50)

1. Coussens LM, Werb Z,. Inflammation and cancer. Nature. 2002; 420: 860-867. (Pubitemid 36019639)
2. Devroede GJ, Taylor WF, Sauer WG, et al. Cancer risk and life expectancy of children with ulcerative colitis. N Engl J Med. 1971; 285: 17-21.
3. Federico A, Morgillo F, Tuccillo C, et al. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer. 2007; 121: 2381-2386. (Pubitemid 350022406)
4. Hussain SP, Harris CC,. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007; 121: 2373-2380. (Pubitemid 350022405)
5. Daig R, Andus T, Aschenbrenner E, et al. Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease. Gut. 1996; 38: 216-222.
6. Keshavarzian A, Fusunyan RD, Jacyno M, et al. Increased interleukin-8 (IL-8) in rectal dialysate from patients with ulcerative colitis: evidence for a biological role for IL-8 in inflammation of the colon. Am J Gastroenterol. 1999; 94: 704-712. (Pubitemid 29124870)
7. Yuan A, Chen JJ, Yao PL, et al. The role of interleukin-8 in cancer cells and microenvironment interaction. Front Biosci. 2005; 10: 853-865.
8. Rajarathnam K, Sykes BD, Kay CM, et al. Neutrophil activation by monomeric interleukin-8. Science. 1994; 264: 90-92. (Pubitemid 24144491)
9. Mazzucchelli L, Hauser C, Zgraggen K, et al. Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation. Am J Pathol. 1994; 144: 997-1007. (Pubitemid 24160640)
10. Ina K, Kusugami K, Yamaguchi T, et al. Mucosal interleukin-8 is involved in neutrophil migration and binding to extracellular matrix in inflammatory bowel disease. Am J Gastroenterol. 1997; 92: 1342-1346. (Pubitemid 27328597)
11. Srikrishna G, Freeze HH,. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia. 2009; 11: 615-628.
12. Gonda TA, Tu S, Wang TC,. Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell Cycle. 2009; 8: 2005-2013.
13. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007; 7: 256-269. (Pubitemid 46486616)
14. Pierce BL, Ballard-Barbash R, Bernstein L, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009; 27: 3437-2344.
15. Slattery ML, Wolff RK, Herrick J, et al. Tumor markers and rectal cancer: support for an inflammation-related pathway. Int J Cancer. 2009; 125: 1698-1704.
16. Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998; 58: 3491-3494. (Pubitemid 28376536)
17. Pagès F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005; 353: 2654-2666. (Pubitemid 41817714)
18. Salama P, Phillips M, Grieu F, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009; 27: 186-192.
19. Abraham C, Cho JH,. Inflammatory bowel disease. N Engl J Med. 2009; 361: 2066-2078.
20. Zisman TL, Rubin DT,. Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol. 2008; 14: 2662-2669.
21. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007; 133: 1099-1105. (Pubitemid 47494461)
22. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004; 126: 451-459. (Pubitemid 38182302)
23. Lakatos PL, Lakatos L,. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol. 2008; 14: 3937-3947.
24. Bonen DK, Cho JH,. The genetics of inflammatory bowel disease. Gastroenterology. 2003; 124: 521-536. (Pubitemid 36169267)
25. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411: 599-603. (Pubitemid 32531408)
26. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001; 411: 603-606. (Pubitemid 32531409)
27. Rioux JD, Daly MJ, Silverberg MS, et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn's disease. Nat Genet. 2001; 29: 223-228. (Pubitemid 32952663)
28. Siminovitch KA,. Advances in the molecular dissection of inflammatory bowel disease. Semin Immunol. 2006; 18: 244-253. (Pubitemid 43922418)
29. Peltekova VD, Wintle RF, Rubin LA, et al. Functional variants of OCTN cation transporter genes are associated with Crohn's disease. Nat Genet. 2004; 36: 471-475. (Pubitemid 38620030)
30. Urban TJ, Yang C, Lagpacan LL, et al. Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4). Pharmacogenet Genomics. 2007; 17: 773-782. (Pubitemid 47263072)
31. Cancer Staging Manual. 7th ed. Berlin: Springer; AJCC, 2010.
32. Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000; 47: 404-409.
33. Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000; 47: 251-255. (Pubitemid 30489769)
34. Martini M, Pallini R, Luongo G, et al. Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme. Int J Cancer. 2008; 123: 2955-2960.
35. Hohaus S, Giachelia M, Di Febo A, et al. Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma. Ann Oncol. 2007; 18: 1376-1381. (Pubitemid 47305013)
36. Stephens M, Smith NJ, Donnelly P,. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001; 68: 978-989. (Pubitemid 32289743)
37. Waller S, Tremelling M, Bredin F, et al. Evidence for association of OCTN genes and IBD5 with ulcerative colitis. Gut. 2006; 55: 809-814. (Pubitemid 43764551)
38. Palmieri O, Latiano A, Valvano R, et al. Variants of OCTN1-2 cation transporter genes are associated with both Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 2006; 23: 497-506. (Pubitemid 43382004)
39. Ullman T, Croog V, Harpaz N, et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology. 2003; 125: 1311-1319. (Pubitemid 37409751)
40. Campbell FC, Maxwell RJ,. Rationale for cancer prevention strategies in high-risk ulcerative colitis. Surgeon. 2009; 7: 96-100.
41. Feagins LA, Souza RF, Spechler SJ,. Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol. 2009; 6: 297-305.
42. Liang JT, Huang KC, Cheng AL, et al. Clinicopathological and molecular biological features of colorectal cancer in patients less than 40 years of age. Br J Surg. 2003; 90: 205-214. (Pubitemid 36237896)
43. Suh JH, Lim SD, Kim JC, et al. Comparison of clinicopathologic characteristics and genetic alterations between microsatellite instability-positive and microsatellite instability-negative sporadic colorectal carcinomas in patients younger than 40 years old. Dis Colon Rectum. 2002; 45: 219-228. (Pubitemid 34141946)
44. Abdullah M, Sudoyo AW, Pranowo BS, et al. Expression of NF-κB and COX-2 in young versus older patients with sporadic colorectal cancer. Acta Med Indones. 2009; 41: 70-74.
45. Atreya I, Atreya R, Neurath MF,. NF-kappaB in inflammatory bowel disease. J Intern Med. 2008; 263: 591-596.
46. Sakamoto K, Maeda S, Hikiba Y, et al. Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin Cancer Res. 2009; 15: 2248-2258.
47. Schottelius AJ, Dinter H,. Cytokines, NF-kappaB, microenvironment, intestinal inflammation and cancer. Cancer Treat Res. 2006; 130: 67-87.
48. Kurzawski G, Suchy J, Kladny J, et al. The NOD2 3020insC mutation and the risk of colorectal cancer. Cancer Res. 2004; 64: 1604-1606. (Pubitemid 38428679)
49. Rahman I, Gilmour PS, Jimenez LA, et al. Ergothioneine inhibits oxidative stress- and TNF-alpha-induced NF-kappa B activation and interleukin-8 release in alveolar epithelial cells. Biochem Biophys Res Commun. 2003; 302: 860-864. (Pubitemid 36294054)
50. Ahmadi A, Polyak S, Draganov PV,. Colorectal cancer surveillance in inflammatory bowel disease: the search continues. World J Gastroenterol. 2009; 15: 61-66.